质谱蛋白定量中验证肽段等摩尔释放的策略:以载脂蛋白(a)为例
该研究以载脂蛋白(a)为模型,采用非最优酶切增强错切肽段鉴定,通过高分辨液相色谱串联质谱映射蛋白至肽段转化,并利用四种同位素变体评估内标线性。研究发现两个定量肽段可隐藏于不同错切肽段中,但在候选参考测量程序中可排除其存在,支持该程序作为Lp(a)检测认证的高阶方法。
要点
- 非最优酶切可增强错切肽段鉴定,用于验证定量肽段是否被隐藏。
- 将隐藏定量肽段的错切肽段纳入MRM列表可警示酶切差异。
- 候选参考测量程序可排除错切肽段干扰,支持其作为高阶方法。
核心结论
- 数据进一步证实apo(a)候选参考测量程序作为商业Lp(a)检测认证高阶方法的有效性,并获国际临床化学与检验医学联合会认可。
研究设计与样本
- 在Leiden载脂蛋白参考实验室对载脂蛋白(a)进行非最优酶切,以增强错切肽段数量,并通过高分辨液相色谱串联质谱鉴定。
- 对含apo(a)定量肽段的错切肽段进行蛋白至肽段转化的详细映射,并应用每种定量肽段的四种同位素变体评估内标线性。
主要发现
- 两个apo(a)定量肽段分别隐藏于两个不同的错切肽段中,被纳入靶向质谱定量MRM列表以警示潜在酶切差异。
- 应用候选参考测量程序进行apo(a)定量时,可排除错切肽段的存在。
临床怎么用
- 在基于质谱的蛋白定量中,应验证定量肽段是否部分隐藏于错切肽段,以确保蛋白至肽段转化完全。
- 可将含定量肽段的错切肽段纳入MRM列表,作为酶切差异的警示指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Quantitative protein mass spectrometry (MS) is ideally suited for precision diagnostics and for reference standardization of protein analytes. At the Leiden Apolipoprotein Reference Laboratory we apply MS strategies to obtain detailed insight into the protein-to-peptide conversion in order to verify that quantifier peptides are not partly concealed in miscleaved protein backbone. METHODS: Apolipoprotein(a) (apo(a)) was digested in a non-optimal manner to enhance the number of miscleaved peptides that were identified by high resolution liquid chromatography tandem-MS measurements. The protein-to-peptide conversion was carefully mapped with specific attention for miscleaved peptides that contain an apo(a) quantifier peptide. Four different isotopologues of each apo(a)-quantifier peptide were applied to evaluate linearity of internal peptide standards during measurement of specific real-life samples. RESULTS: Two apo(a) quantifier peptides that were concealed in two different miscleaved peptides were included into a multiple reaction monitoring list in our targeted MS-based apo(a) quantifications to alert for potential protein digestion discrepancies. The presence of miscleaved peptides could be ruled out when applying our candidate reference measurement procedure (RMP) for apo(a) quantification. CONCLUSIONS: These data further corroborate the validity of our apo(a) candidate RMP as higher order method for certification of commercial Lp(a) tests that is endorsed by the International Federation of Clinical Chemistry and Laboratory Medicine. MS-based molecular detection and quantification of heterogeneous apo(a) proteoforms will allow manufacturers' transitioning from confounded lipoprotein(a) [Lp(a)] mass levels into accurate molar apo(a) levels.
引用
- van der Burgt YEM, Romijn FPHTM, Treep MM, et al. Strategies to verify equimolar peptide release in mass spectrometry-based protein quantification exemplified for apolipoprotein(a). Clin Chem Lab Med. 2024. PMID: 39450666. doi:10.1515/cclm-2024-0539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。